Levitate Bio

Executive Summary

Levitate Bio is a Cambridge-based biotechnology company that offers a sophisticated software platform for protein engineering and design. The platform curates and automates tools from the Rosetta Commons, augmented with artificial intelligence, enabling researchers to design proteins for therapeutic, diagnostic, and other applications without requiring deep coding expertise. Founded in 2020, the company was spun out of Cyrus Biotechnology in 2024 and is wholly owned by the Rosetta Commons Foundation. By lowering the technical barrier to advanced protein design, Levitate Bio aims to accelerate drug development and broaden access to computational protein engineering.

Upcoming Catalysts (preview)

• Q3 2026Launch of AI-enhanced protein design module70% success
• Q4 2026Strategic partnership with a major pharmaceutical company60% success
• Q2 2026Series A funding round announcement65% success